Georgia is currently home to 1930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Grady Memorial Hospital, Atlanta, Georgia
Conditions: Acute Coronary Syndrome
Register for Updates
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/17/2025
Locations: Skin Care Physicians of Georgia, Macon, Georgia
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/17/2025
Locations: Augusta University, Augusta, Georgia
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142
Recruiting
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.
Gender:
MALE
Ages:
1 year and above
Trial Updated:
07/17/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004
Recruiting
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Winship Cancer Institute, Atlanta, Georgia
Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC, Colorectal Cancer
Register for Updates
A Study of Daratumumab
NCT05438043
Recruiting
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/17/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973
Recruiting
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethni... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Winship Cancer Institute Emory University, Atlanta, Georgia
Conditions: Amyloidosis
Register for Updates
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781
Recruiting
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269
Recruiting
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/17/2025
Locations: Children's Center For Digestive Healthcare, Llc, Atlanta, Georgia
Conditions: Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Register for Updates
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173
Recruiting
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/17/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
Register for Updates
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04786574
Recruiting
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 4 weeks and 12 weeks
Trial Updated:
07/17/2025
Locations: Research Site #100, Atlanta, Georgia
Conditions: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Register for Updates
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
NCT04662580
Recruiting
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Metastatic Prostate Cancer
Register for Updates